Talk:Adverum Biotechnologies

Update Request to Adverum Bio

 * What I think should be changed: Key People in the box on the right:
 * Why it should be changed: It is no longer accurate:
 * References supporting the possible change (format using the "cite" button):

Update names for accuracy and remove names no longer listed on the website: Laurent Fischer, M.D., Chief Executive officer Leone Patterson, President & Chief Financial Officer Peter Soparkar, J.D., Chief Legal Officer Angela Thedinga, MBA, MPH, Chief Technology Officer

SKM.SamBrown (talk) 20:45, 6 April 2021 (UTC) Suzanne Madore


 * Done. Cordless Larry (talk) 07:13, 7 April 2021 (UTC)

Update Request to Adverum Bio

 * What I think should be changed (include citations):

1. The pipeline listed needs to be updated 2. Text in the first paragraph needs to be updated ...is a clinical-stage gene therapy company headquartered in Redwood City, California with a GMP manufacturing facility in Durham, North Carolina. The company is targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, designed as a one-time, intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD).[3] and diabetic macular edema (DME) .

3. Update to last paragraph: ADVM-022 is currently being evaluated in a Phase 2 trial for DME called INFINITY (NCT04418427).


 * Why it should be changed:

1. It has recently been updated 2. Language has been updated for specificity and legal requests. 3. This is a recent update for ADVM-022

SKM.SamBrown (talk) 13:49, 26 April 2021 (UTC)Suzanne Madore, Sam Brown Communications, agency of record for Adverum Bio

SKM.SamBrown (talk) 13:49, 26 April 2021 (UTC)


 * Edited to include mention of DME. Also edited the information for conciseness and clarity, as some of the details weren't suitable for the lead section. Stonkaments (talk) 19:34, 26 April 2021 (UTC)